{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:50:58Z","timestamp":1792180258692,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":58,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"Kankerbestrijding\/KWF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ejca.2019.09.013","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T05:48:37Z","timestamp":1571809717000},"page":"28-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza E.L.","family":"Hendriks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Dooms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Berghmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4798-8899","authenticated-orcid":false,"given":"Antonin","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baktiar","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Giaj Levra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccolo","family":"Giaj Levra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vansteenkiste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.09.013_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2019.09.013_bib2","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2019.09.013_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2013.07.023","article-title":"Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors","volume":"82","author":"Griffioen","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2019.09.013_bib4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0003-4975(00)02509-1","article-title":"Resection of adrenal metastases from non-small cell lung cancer: a multicenter study","volume":"71","author":"Porte","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ejca.2019.09.013_bib5","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1200\/JCO.2007.14.2091","article-title":"Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis","volume":"26","author":"Tanvetyanon","year":"2008","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2019.09.013_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2013.07.026","article-title":"Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature","volume":"82","author":"Ashworth","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2019.09.013_bib7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cllc.2014.04.003","article-title":"An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer","volume":"15","author":"Ashworth","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2019.09.013_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00066-011-2192-z","article-title":"Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer","volume":"187","author":"Holy","year":"2011","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ejca.2019.09.013_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/JTO.0b013e318262caf6","article-title":"Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450)","volume":"7","author":"De Ruysscher","year":"2012","journal-title":"J Thorac Oncol : Offic Publ Int Assoc Stud Lung Cancer"},{"key":"10.1016\/j.ejca.2019.09.013_bib10","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol : Offic J Eur Soc Med Oncol\/ESMO"},{"key":"10.1016\/j.ejca.2019.09.013_bib11","series-title":"NCCN guidelines non-small cell lung cancer","year":"2019"},{"key":"10.1016\/j.ejca.2019.09.013_bib12","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1097\/JTO.0000000000000673","article-title":"The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer","volume":"10","author":"Eberhardt","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2019.09.013_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2019.09.013_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.08.269","article-title":"Phase II study of pembrolizumab for oligometastatic Non-small cell lung cancer (NSCLC) following completion of locally ablative therapy (LAT)","volume":"13","author":"Bauml","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2019.09.013_bib15","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. Maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol : Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2019.09.013_bib16","article-title":"MA25.02 - searching for a definition of synchronous oligometastatic (sOMD)-NSCLC: a consensus from thoracic Oncology experts","volume":"10","author":"Dingemans","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2019.09.013_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2019.05.037","article-title":"Defining synchronous oligometastatic non-small cell lung cancer: a systematic review","author":"GiajLevra","year":"2019","journal-title":"J Thorac Oncol : Offic Publ Int Assoc Stud Lung Cancer"},{"key":"10.1016\/j.ejca.2019.09.013_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.08.529","article-title":"MA25.01 \u2013 EORTC lung cancer group survey to define synchronous oligometastatic disease in NSCLC","volume":"13","author":"Levy","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2019.09.013_bib19","series-title":"P3.09-004 - oligometastatic non-small cell lung cancer: a simulation expert multidisciplinary tumor board. World Conference on Lung Cancer, Sydney","author":"Dooms","year":"2013"},{"key":"10.1016\/j.ejca.2019.09.013_bib20","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J Thorac Oncol : Offic Publ Int Assoc Stud Lung Cancer"},{"key":"10.1016\/j.ejca.2019.09.013_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol : Offic Publ Int Assoc Stud Lung Cancer"},{"key":"10.1016\/j.ejca.2019.09.013_bib22","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.09.013_bib23","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.09.013_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2017.09.433","article-title":"OA 17.08 phase II study of pembrolizumab for oligometastatic non-small cell lung cancer (NSCLC) following completion of locally ablative therapy (LAT)","volume":"12","author":"Bauml","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2019.09.013_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2017.12.012","article-title":"Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group","volume":"91","author":"deSouza","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.09.013_bib26","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jtho.2018.07.098","article-title":"Progression-Free-Survival and Overall Survival beyond 5 years of non-small cell lung cancer patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450)","volume":"13","author":"De Ruysscher","year":"2018","journal-title":"J Thorac Oncol : Offic Publ Int Assoc Stud Lung Cancer"},{"key":"10.1016\/j.ejca.2019.09.013_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020690","article-title":"Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer","volume":"8","author":"Conibear","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2019.09.013_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lungcan.2015.03.023","article-title":"A new PET\/CT volumetric prognostic index for non-small cell lung cancer","volume":"89","author":"Zhang","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2019.09.013_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00259-014-2903-7","article-title":"Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis","volume":"42","author":"Im","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2019.09.013_bib30","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/cncr.30058","article-title":"Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)","volume":"122","author":"Wong","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.09.013_bib31","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.18632\/oncotarget.2920","article-title":"14q32-encoded microRNAs mediate an oligometastatic phenotype","volume":"6","author":"Uppal","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2019.09.013_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050141","article-title":"Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs","volume":"7","author":"Lussier","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2019.09.013_bib33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.radonc.2017.11.006","article-title":"Prognostic value of combining a quantitative image feature from positron emission tomography with clinical factors in oligometastatic non-small cell lung cancer","volume":"126","author":"Jensen","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2019.09.013_bib34","doi-asserted-by":"crossref","first-page":"517","DOI":"10.21037\/tlcr.2016.10.15","article-title":"Liquid biopsy in early stage lung cancer","volume":"5","author":"Perez-Ramirez","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2019.09.013_bib35","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41467-018-04278-6","article-title":"Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis","volume":"9","author":"Pitroda","year":"2018","journal-title":"Nat Commun"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491930735X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491930735X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:24:51Z","timestamp":1760732691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491930735X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":35,"alternative-id":["S095980491930735X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.09.013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}